---
schema_version: "secwatch.filing_event.v1"
accession: "0001479290-23-000114"
form_type: "8-K"
ticker: null
cik: "0001479290"
company_name: "Revance Therapeutics, Inc."
filed_at: "2023-12-15T23:59:59+00:00"
generated_at: "2026-06-07T11:50:00.699198+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# Revance Therapeutics adopts amended bylaws aligning with SEC Rule 14a-19 on universal proxy

## Summary
- Aligns director nomination and proxy solicitation with Rule 14a-19, requiring 67% voting power solicitation evidence.
- Enhances disclosure requirements for nominating stockholders, nominees, and their associates and affiliates.
- Removes references to California law and updates electronic notice provisions per Delaware DGCL changes.
- Effective immediately as of December 12, 2023, following Board approval.
- Includes immaterial modifications, conforming edits, and removal of loan-to-officers provision.

## SEC filing metadata
- accession: 0001479290-23-000114
- form_type: 8-K
- cik: 0001479290
- company_name: Revance Therapeutics, Inc.
- filed_at: 2023-12-15T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1479290/000147929023000114/0001479290-23-000114-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1479290/000147929023000114/rvnc-20231212.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001479290-23-000114
- JSON: https://secwatch.observer/filing/0001479290-23-000114.json
- Plain text: https://secwatch.observer/filing/0001479290-23-000114.txt

## Key facts
- Governance Changes
  Revance Therapeutics, Inc.: Amended and Restated Bylaws to align with Rule 14a-19, enhance director nomination disclosures, and make other updates (effective 2023-12-12).
  - Change: bylaw amendment
  - Effective: 2023-12-12
  source text: On December 12, 2023, in connection with the effectiveness of Rule 14a-19 ("Rule 14a-19") under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), certain changes to the General Corporation Law of the State of Delaware (the "DGCL") and a periodic review of corporate governance matters, the board of directors (the "Board") of Revance Therapeutics, Inc. (the "Company"), approved and adopted the Amended and Restated Bylaws of the Company (as so amended and restated, the "Amended and Restated Bylaws"), effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1479290/000147929023000114/0001479290-23-000114-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.